TB treatment

Active tuberculosis (TB) disease is treated with a combination of antibiotics. Successful treatment usually requires at least six months of therapy, without missing doses. People living with HIV also need to take HIV treatment, but it may be started a few weeks after TB treatment. Care is needed when taking TB and HIV treatment at the same time.

Other topics in this section

TB treatment: latest news

TB treatment resources

  • Tuberculosis

    Tuberculosis (TB) is an infection that usually affects the lungs.It can be very serious, particularly for people living with HIV who have a low CD4 count.TB can...

    From: Factsheets

    Information level Level 2

  • Treatment for TB and HIV

    If tuberculosis (TB) is making you ill and you also have HIV, then you usually need to take treatment for both TB and HIV.You can...

    From: The basics

    Information level Level 1

  • HATIP #39, 5th January 2005

    Risk of TB doubles in first year of HIV infection http://www.aidsmap.com/en/news/95D84EF4-94DE-41FD-B20C-3247321E70DA.asp?hp=1 The risk of developing tuberculosis doubles within the first year of testing HIV positive, according to...

    From: HIV & AIDS treatment in practice

    Information level Level 4

TB treatment features

TB treatment in your own words

TB treatment news from aidsmap

More news

TB treatment news selected from other sources

  • Will a new TB treatment be available soon?

    Experts advising the U.S. Food and Drug Administration on marketed and investigational drugs for infectious diseases and disorders were divided on whether the regulatory agency should approve a new drug as part of a proposed combination therapy for highly resistant tuberculosis. The majority of the independent experts — 14 out of 18 — advising the regulatory agency voted favorably last month. But the remaining four found insufficient evidence on efficacy and safety of the TB Alliance’s oral anti-TB drug pretomanid when used in combination with bedaquiline and linezolid, or BPaL.

    08 July 2019 | Devex

  • Will new TB treatments reach those who need them most?

    Pharma giant GlaxoSmithKline is pursuing new treatments for tuberculosis but insists it will need support from governments and funding agencies if it is to get them to patients in lower-income countries, the head of its global health unit, David Barros-Aguirre, told Devex.

    15 April 2019 | Devex

  • Double doses of darunavir given with rifampicin lead to high rates of hepatoxicity

    Adjusted doses of darunavir/ritonavir (DRV/r) with rifampicin (RIF) were associated with unacceptable risk of hepatotoxicity and a reduction in DRV trough concentrations in a pharmacokinetic (PK) study, conducted in South Africa, presented at CROI 2019.


    12 March 2019 | HIV i-Base

  • Pulmonary TB can be cured with shorter treatment, study finds

    New data analysis uses precision medicine approach to demonstrate treatment efficacy. When patients were retrospectively stratified into minimal, moderate and severe disease categories, the four-month drug regimens turned out to have been highly effective for the 47 percent of patients with minimal disease. But the four-month regimens were not effective for patients with moderate or severe disease. And even the standard six-month treatment was insufficient for those with the most extensive disease.

    06 November 2018 | Eurekalert Inf Dis

  • Ending tuberculosis will take lower drug prices and a new, improved innovation ecosystem

    Prisha and millions of other people with tuberculosis and drug-resistant tuberculosis do not need more patents for drugs they can’t afford. Instead, they need a better system with new incentives. They need real innovation. And right now they need a political declaration from the U.N.’s high-level meeting on tuberculosis that reaffirms countries’ legal right to use TRIPS flexibilities when they cannot otherwise afford the lifesaving treatments that Prisha and millions like her desperately need.

    13 September 2018 | STAT

  • SimpliciTB Clinical Trial Launched with First Patients in Tbilisi, Georgia

    New pivotal trial examines potential of BPaMZ regimen to shorten treatment for tuberculosis and multidrug-resistant tuberculosis.

    28 August 2018 | TB Alliance

  • How smartphones are becoming a weapon in the global fight against tuberculosis

    Mobile technologies devised by researchers at the University of California, San Diego, and Johns Hopkins are allowing patients to use their phones to record daily medication intake. The encrypted videos are sent to public health workers who can watch them from their cubicles, instead of traveling long distances every day to visit patients at their homes or workplaces.

    21 August 2018 | STAT

  • South Africa strikes deal on new TB drug as WHO revisits guidance

    The World Health Organization could soon start promoting a new tuberculosis drug that is now more affordable after South Africa brokered a deal with a pharmaceutical company to slash the price by half.

    13 August 2018 | Devex

  • AIDS 2018: Price of bedaquiline drops in South Africa, will replace injectable TB drugs, Minister of Health announces

    South Africa has signed a deal with bedaquiline manufacturer Jannsen pharmaceuticals to drop the price of the drug from $750 for a full course to $400, for the next eight months,Minister of Health Aaron Motsoaledi announced here today.

    23 July 2018 | Science Speaks

  • Higher doses of rifampin appear more effective in fighting TB without increasing risk of adverse events

    Higher daily doses of rifampin, a cornerstone of tuberculosis treatment, killed more TB bacteria in sputum cultures, and the higher doses did so without increasing the adverse effects of treatment, according to a randomized controlled trial published online in the American Thoracic Society's American Journal of Respiratory and Critical Care Medicine.

    29 June 2018 | Eurekalert Inf Dis
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.

See also

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.